As of June 29, almost all foreign pharmaceutical companies suspended clinical trials in the Russian Federation because of issues with timely delivery of biomaterials to labs.
If biomaterials are not delivered on time, the trial is considered failed, so companies have suspended clinical trials in Russia in order not to lose money.
